References
- LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry2004161915615000267
- Canadian Psychiatric AssociationClinical practice guidelines. Treatment of schizophreniaCan J Psychiatry20055013 Suppl 1S7S57
- CorrellCUMalhotraAKKaushikSMcMenimanMKaneJMEarly prediction of antipsychotic response in schizophreniaAm J Psychiatry2003160112063206514594760
- KinonBJChenLAscher-SvanumHPredicting response to atypical antipsychotics based on early response in the treatment of schizophreniaSchizophr Res20081021–323024018423985
- Ascher-SvanumHNyhuisAWFariesDEClinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophreniaSchizophr Bull20083461163117118156640
- AgidOKapurSArenovichTZipurskyRBDelayed-onset hypothesis of antipsychotic action: A hypothesis tested and rejectedArch Gen Psychiatry200360121228123514662555
- LeuchtSBuschRHamannJKisslingWKaneJMEarly-onset hypothesis of antipsychotic drug action: A hypothesis tested, confirmed and extendedBiol Psychiatry200557121543154915953491
- KinonBJChenLAscher-SvanumHEarly response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophreniaNeuropsychopharmacology201035258159019890258
- KinonBJChenLAscher-SvanumHChallenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophreniaSchizophr Res20101181–317618220080036
- American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth EditionNew York, NYAmerican Psychiatric Publishing Inc2000
- OverallJEGorhamDRThe Brief Psychiatric Rating ScalePsychol Rep196210799812
- KaySROplerLAFiszbeinAPositive and Negative Syndrome Scale (PANSS) User’s ManualNorth Tonawanda, NYMulti-Health Systems Inc2000
- GuyWECDEU Assessment Manual for PsychopharmacologyPublication ADM 76-338 Revised.Rockville, MDUS Department of Health, Education, and Welfare1976
- GoldMRSiegelJERussellLBWeinsteinMCCost-Effectiveness in Health and Medicine1st edNew York, NYOxford University Press1996
- KaneJMKimEKanHJComparative utility of aripiprazole and haloperidol in schizophrenia: Post hoc analysis of two 52-week, randomized, controlled trialsAppl Health Econ Health Policy20097210911919731968
- LenertLASturleyAPRapaportMHPublic preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scoresSchizophr Res200471115516515374583
- LenertLASturleyAPRapaportMHCorrigendum to “Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores”Schizophr Res2005801135136
- SimpsonGMAngusJWA rating scale for extrapyramidal side effectsActa Psychiatr Scand Suppl197021211194917967
- BarnesTRA rating scale for drug-induced akathisiaBr J Psychiatry19891546726762574607
- National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS)ECDEU Assessment Manual for Psychopharmacology, RevisedRockville, MDUS National Institute of Health1976
- MohrPEChengCMClaxtonKThe heterogeneity of schizophrenia in disease statesSchizophr Res2004711839515374576
- MahmoudRAEngelhartLMJanagapCCOsterGOllendorfDRisperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: Symptoms, quality of life and resource use under customary clinical careClin Drug Investig2004245275286
- Analysource Data [Website on the Internet]AWP Cost of Antipsychotics Available from: http://www.analysource.com. Accessed March 31, 2008.
- RosenheckRALeslieDLSindelarJCost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophreniaAm J Psychiatry2006163122080208917151158
- FariesDLeonAHaroJObenchainRAnalysis of Observational Health Care Data Using SASCary, NCSAS Press2010
- ObenchainRLRobinsonRLSwindleRWCost-effectiveness inferences from bootstrap quadrant confidence levels: Three degrees of dominanceJ Biopharm Stat200515341943615920889
- PolskyDDoshiJABauerMSGlickHAClinical trial-based cost-effectiveness analyses of antipsychotic useAm J Psychiatry2006163122047205617151153